Search

Your search keyword '"Socie G"' showing total 670 results
Start Over Author "Socie G"
670 results on '"Socie G"'

2. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Author

Passweg, J.R., Labopin, M., Christopeit, M., Cornelissen, J., Pabst, T., Socié, G., Russel, N., Yakoub-Agha, I., Blaise, D., Gedde-Dahl, T., Labussière-Wallet, H., Malladi, R., Forcade, E., Maury, S., Polge, E., Lanza, F., Gorin, N.C., Mohty, M., and Nagler, A.

Published
2020
Full Text
View/download PDF

3. P087 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: APPLICABILITY OF IPSS-M IN MYELODYSPLASTIC SYNDROMES ARISING FROM APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Author

Gurnari, C., Prata, P., Catto, L.F. Bazzo, Durmaz, A., Larcher, L., Sébert, M., Allain, V., Kewan, T., Pagliuca, S., Pinto, A., Inacio, M.C.B., Hernandez, L., Dhedin, N., Caillat-Zucman, S., Clappier, E., De Fontbrune, F.S., Voso, M.T., Visconte, V., De Latour, R. Peffault, Jean, S., Socié, G., Calado, R., and Maciejewski, J.

Published
2023
Full Text
View/download PDF

4. Total body irradiation/fludarabine versus busulfan/fludarabine as conditioning in all patients > 45 years in 1sr CR - a registry-based study by the ALWP of the EBMT [Abstract]

Author

Hirschbühl, Klaus, Labopin, M., Polge, E., Schmid, Christoph, Blaise, D., Bourhis, J. H., Socie, G., Forcade, E., Yakoub-Agha, I., Labussiere-Wallet, H., Bethge, W., Chevallier, P., Fegueux, N., Stelljes, M., Spyridonidis, A., Peric, Z., Brissot, E., Savani, B., Giebel, S., Nagler, A., and Mohty, M.

Subjects
ddc:610
Published
2022

5. Allogeneic stem cell transplantation for acute myeloid leukemia with normal cytogenetics (CN-AML): outcome, risk factors and role of molecular subgroups in 1006 patients - a report from the Acute Leukemia Working Party of EBMT [Abstract]

Author

Schmid, Christoph, Labopin, M., Socie, G., Rambaldi, A., Schwerdtfeger, R., Deconinck, E., Vigouroux, S., Huynh, A., Volin, L., Bourhis, J.-H., Maertens, J., Chevalier, P., Jindra, P., Schlimok, G., Cornelissen, J., Ifrah, N., Nagler, A., Polge, E., Esteve, J., and Mohty, M.

Published
2022

8. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC

Author

Tessoulin, B, Ceballos, P, Chevallier, P, Blaise, D, Tournilhac, O, Gauthier, J, Maillard, N, Tabrizi, R, Choquet, S, Carras, S, Ifrah, N, Guillerm, G, Mohty, M, Tilly, H, Socie, G, Cornillon, J, Hermine, O, Daguindau, É, Bachy, E, Girault, S, Marchand, T, Oberic, L, Reman, O, Leux, C, and Le Gouill, S

Published
2016
Full Text
View/download PDF

15. HCT outcome in adult patients with Fanconi anemia: WP41

Author

Bierings, M., Bonfim, C., Aljurf, M., Mehta, P., de la Tour, Peffault R., Knol, C., Sucak, G., Othman, T. B., Socie, G., Thomson, K., McQuaker, G., Esquirol, A., Zecca, M., Boulad, F., Kroger, N., Michallet, M., Risitano, A., Ehninger, G., Porcher, R., and Dufour, C.

Published
2016

16. Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients (Bone Marrow Transplantation, (2020), 55, 6, (1114-1125), 10.1038/s41409-020-0803-y)

Author

Spyridonidis A., Labopin M., Savani B. N., Niittyvuopio R., Blaise D., Craddock C., Socie G., Platzbecker U., Beelen D., Milpied N., Cornelissen J. J., Ganser A., Huynh A., Griskevicius L., Giebel S., Aljurf M., Brissot E., Malard F., Esteve J., Peric Z., Baron F., Ruggeri A., Schmid C., Gilleece M., Gorin N. -C., Lanza F., Shouval R., Versluis J., Bug G., Floisand Y., Ciceri F., Sanz J., Bazarbachi A., Nagler A., Mohty M., Spyridonidis, A., Labopin, M., Savani, B. N., Niittyvuopio, R., Blaise, D., Craddock, C., Socie, G., Platzbecker, U., Beelen, D., Milpied, N., Cornelissen, J. J., Ganser, A., Huynh, A., Griskevicius, L., Giebel, S., Aljurf, M., Brissot, E., Malard, F., Esteve, J., Peric, Z., Baron, F., Ruggeri, A., Schmid, C., Gilleece, M., Gorin, N. -C., Lanza, F., Shouval, R., Versluis, J., Bug, G., Floisand, Y., Ciceri, F., Sanz, J., Bazarbachi, A., Nagler, A., and Mohty, M.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

17. Allogreffe dans les lymphomes T cutanés avancés (CUTALLO) : une étude prospective contrôlée multicentrique, appariée par score de propension

Author

De Masson, A., Beylot-Barry, M., Ram-Wolff, C., Méar, J.B., Dalle, S., D’incan, M., Oro, S., Orvain, C., Abraham, J., Dereure, O., Charbonnier, A., Cornillon, J., Longvert, C., Barete, S., Boulinguez, S., Wierzbicka-Hainaut, E., Aubin, F., Rubio, M.T., Bernard, M., Schmidt-Tanguy, A., Houot, R., Pham-Ledard, A., Michonneau, D., Brice, P., Labussière-Wallet, H., Bouaziz, J.D., Grange, F., Moins-Teisserenc, H., Jondeau, K., Michel, L., Mourah, S., Battistella, M., Daguindau, E., Loschi, M., Picard, A., Franck, N., Maillard, N., Huynh, A., Nguyen, S., Marcais, A., Chaby, G., Ceballos, P., Le Corre, Y., Maury, S., Bay, J.O., Adamski, H., Bachy, E., Forcade, E., Socié, G., Bagot, M., Chevret, S., and Peffault De Latour, R.

Published
2023
Full Text
View/download PDF

19. Total body irradiation plus fludarabine compared to busulfan plus fludarabine as 'reduced-toxicity conditioning' for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

Author

Giebel, S, Labopin, M, Sobczyk-Kruszelnicka, M, Stelljes, M, Byrne, JL, Fegueux, N, Beelen, DW, Rovira, M, Spyridonidis, A, Blaise, D, Bornhauser, M, Karadogan, I, Savani, BN, Nagler, A, Mohty, M, Martin, S, Chevallier, P, Neubauer, A, Damaj, G, Koc, Y, Ganser, A, Collin, M, Yakoub-Agha, I, Ozdogu, H, Araujo, MC, Itala-Remes, M, Orchard, K, Isaksson, C, Bethge, W, Martin, H, Aljurf, M, Faber, E, Caballero, D, Zak, P, Leleu, X, Bay, JO, Rohrlich, PS, Kroger, N, Huynh, A, Schafer-Eckart, K, Milpied, N, Lenhoff, S, Ho, A, Lopez, JLB, Mordini, N, Lioure, B, Halaburda, K, Olivieri, A, Gedde-Dahl, T, Protheroe, R, Tischer, J, Klammer, M, Clausen, J, Potter, V, Ladetto, M, Tilly, H, Deconinck, E, Brecht, A, Muller, LP, Heinicke, T, Carrete, JPT, Bazarbachi, A, Remenyi, P, Rubio, MT, Fanin, R, Perez-Simon, JA, Niels, M, Diez-Martin, JL, Arat, M, Hermine, O, Socie, G, Cornelissen, JJ, Santarone, S, Guyotat, D, Bulabois, CE, Bernasconi, P, Johansson, JE, Vrhovac, R, Greinix, H, Lorenzo, JLL, Apte, S, Craddock, C, Kobbe, G, Zahrani, MA, Dreger, P, Lange, A, Tbakhi, A, Meijer, E, Llamas, CV, Santasusana, JMR, Corradini, P, Benedetti, F, Rambaldi, A, Gandemer, V, Malfuson, JV, Kaare, A, Risitano, A, Petrini, M, Selleri, C, and Wu, DP

Abstract

The optimal conditioning for patients with acute myeloid leukemia in first complete remission treated with allogeneic hematopoietic cell transplantation (allo-HCT) has not been defined so far. In this retrospective study, we compared two "reduced-toxicity" regimens: intravenous busulfan at a total dose of 9.6 mg/kg (3 days) + fludarabine (Bu3/Flu) and total body irradiation at a dose of 8 Gy + fludarabine (TBI8Gy/Flu). In the entire study cohort (n = 518), the probabilities of overall survival (OS), leukemia-free survival (LFS), relapse and non-relapse mortality (NRM) at 2 years for Bu3/Flu and TBI8Gy/Flu were 62% vs. 72.5% (p = 0.051), 59.5% vs. 65% (p = 0.15), 30% vs. 20% (p = 0.01), and 10% vs. 14% (p = 0.18), respectively. In multivariate model for patients

Published
2021

20. ELTROMBOPAG ADDED TO STANDARD IMMUNOSUPPRESSION IMPROVES RESPONSE RATE IN SEVERE APLASTIC ANEMIA: RESULTS OF THE MULTICENTER PHASE III PROSPECTIVE RANDOMIZED RACE TRIAL

Author

Risitano, AM, Kulasekararaj, A, Iacobelli, S, Terwel, S, Hill, A, Halkes, CJM, Recher, C, Barraco, F, Forcade, E, Llamas, JCV, Drexler, B, Mear, JB, Van Lint, MT, Raymakers, RAP, De Groot, MR, Daguindau, E, Nur, E, Barcellini, W, Russell, NH, Terriou, L, Iori, AP, Sanchez-Ortega, I, Xicoy, B, Jarque, I, Cavenagh, J, De Fontbrune, FS, Marotta, S, Munir, T, Tjon, JML, Tavitian, S, Praire, A, Clement, L, Rabian, F, Smith, AE, Cook, R, Marano, L, Griffin, M, Palmisani, E, Muus, P, Cacace, F, Frieri, C, Passweg, JR, Marsh, JCW, Socie, G, Mufti, GJ, Dufour, C, and de Latour, RP

Published
2021

31. ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH NORMAL CYTOGENETICS (CN-AML): OUTCOME, RISK FACTORS AND ROLE OF MOLECULAR SUBGROUPS IN 1006 PATIENTS - A REPORT FROM THE ACUTE LEUKEMIA WORKING PARTY OF EBMT: PH-O127

Author

Schmid, C., Labopin, M., Socie, G., Rambaldi, A., Schwerdtfeger, R., Deconinck, E., Vigouroux, S., Huynh, A., Volin, L., Bourhis, J.-H., Maertens, J., Chevalier, P., Jindra, P., Schlimok, G., Cornelissen, J., Ifrah, N., Nagler, A., Polge, E., Esteve, J., and Mohty, M.

Published
2014

33. Results of the Ebmt Saawp Phase III Prospective Randomized Multicenter Race Study of Horse Atg and Ciclosporin with or Without Eltrombopag in Naive Saa Patients

Author

de Latour, RP, Marsh, J, Iacobelli, S, Terwel, S, Hill, A, Halkes, CJM, Recher, C, Barraco, F, Forcade, E, Llamas, JCV, Dresler, B, Mear, JB, Van Lint, MT, Raymakers, RAP, De Groot, MR, Daguindau, E, Nur, E, Barcellini, W, Russell, NH, Terriou, L, Iori, AP, Sanchez-Ortega, I, Xicoy, B, Jarque, I, Cavenagh, J, de Fontbrune, FS, Kulasekararaj, A, Marotta, S, Munir, T, Tjon, JML, Tavitian, S, Praire, A, Clement, L, Rabian, F, Smith, AE, Cook, R, Marano, L, Griffin, M, Palmisani, E, Muus, P, Cacace, F, Passweg, JR, Socie, G, Mufti, GJ, Dufour, C, and Risitano, A

Published
2020

34. Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel

Author

Bonifazi F, Rubio M, Bacigalupo A, Boelens J, Finke J, Greinix H, Mohty M, Nagler A, Passweg J, Rambaldi A, Socie G, Solano C, Walker I, Barosi G, and Kroger N

Subjects
surgical procedures, operative
Abstract

This collaborative initiative aimed to provide recommendations on the use of polyclonal antithymocyte globulin (ATG) or anti-T lymphocyte globulin (ATLG) for the prevention of graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HSCT). A comprehensive review of articles released up to October, 2018 was performed as a source of scientific evidence. Fourteen clinically relevant key questions to the domains indication, administration, and post-transplant management were developed and recommendations were produced using the Delphi technique involving a Panel of 14 experts. ATG/ATLG was strongly recommended as part of myeloablative conditioning regimen prior to matched or mismatched unrelated bone marrow or peripheral blood allogeneic HSCT in malignant diseases to prevent severe acute and chronic GvHD. ATG/ATLG was also recommended prior to HLA-identical sibling peripheral HSCT with good but lesser bulk of evidence. In reduced intensity or nonmyeloablative conditioning regimens, ATG/ATLG was deemed appropriate to reduce the incidence of acute and chronic GvHD, but a higher risk of relapse should be taken into account. Recommendations regarding dose, application, and premedication were also provided as well as post-transplant infectious prophylaxis and vaccination. Overall, these recommendations can be used for a proper and safe application of polyclonal ATG/ATLG to prevent GvHD after allogeneic HSCT.

Published
2020

35. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

Author

Zeiser, R., von Bubnoff, N., Butler, J., Mohty, M., Niederwieser, D., Or, R., Szer, J., Wagner, E. M., Zuckerman, T., Mahuzier, B., Xu, J., Wilke, C., Gandhi, K. K., Socie, G, Sung-Soo, Yoon, Chulwon, Jung, Tobias, Gedde-Dahl, Marwan, Shaheen, Jose Antonio Perez Simon, Jose Valentin Garcia Gutierrez, Jaime Sanz Caballer, Rafael Duarte Palomino, David Valcarcel Ferreiras, Cristina Diaz de Heredia Rubio, Kwon, Mi, Maria Del Carmen Martinez Munoz, Soledad, Gonzalez, Matilde Rodriguez Ruiz, Inmaculada Heras Fernando, Maria Pascual Cascon, Ana Sastre Urgelles, Marta Gonzalez Vicent, Jose Maria Fernandez Navarro, Yvonne, Björk, Kristina, Carlson, Jih-Luh, Tang, Su-Peng, Yeh, Ronjon, Chakraverty, Robert, Wynn, Lajos, Floro, Brian Thomas Kornblit, Jason, Butler, David, Ritchie, John, Kwan, Jacqueline, Fleming, Duncan, Purtill, Georg, Hopfinger, Hildegard, Greinix, Johannes, Clausen, Dennis, Kim, Natasha, Kekre, Imran, Ahmad, Brian, Leber, Andrew, Daly, Gizelle, Popradi, Jennifer, White, Mohamed, Elemary, Gerard, Socie, Valérie, Coiteux, Patrice, Chevallier, Claude-Eric, Bulabois, Helene, Labussiere-Wallet, Mohamad, Mohty, Pierre-Simon, Rohrlich, Edouard, Forcade, Fabrice, Larosa, Sylvie, Francois, Stephanie N'Guyen Quoc, Marie-Therese, Rubio, Jean-Hughes, Dalle, Marie, Ouachee-Chardin, Benedicte, Bruno, Anne, Huynh, Nathalie, Fegueux, Jerome, Cornillon, Pascal, Turlure, Nikolas von Bubnoff, Georg-Nikolaus, Franke, Friedrich, Stoelzel, Matthias, Eder, Arne, Brecht, Nicolaus, Kroeger, Nina-Kristin, Steckel, Eva, Wagner, Guido, Kobbe, Wolfgang, Bethge, Matthias, Stelljes, Donald, Bunjes, Igor, Blau, Ingo, Mueller, Stefan, Klein, Christoph, Schmid, Lena, Oevermann, Herrad, Baurmann, Inken, Hilgendorf, Klaus Daniel Stachel, Yok-Lam, Kwong, Ron, Ram, Batya, Avni, Moshe, Yeshurun, Tsila, Zuckerman, Riccardo, Saccardi, Paolo, Corradini, Franco, Locatelli, Alessandro, Rambaldi, Andrea, Bacigalupo, Attilio, Olivieri, Francesca, Patriarca, Giovanni, Grillo, Francesca, Bonifazi, Edoardo, Lanino, Attilio, Rovelli, Benedetto, Bruno, Russo, Domenico, Maurizio, Musso, Marco, Zecca, Franca, Fagioli, Angelo Michele Carella, Stefania, Bregante, Roberto, Sorasio, Takanori, Teshima, Koichi, Miyamura, Kiyoshi, Ando, Hirohisa, Nakamae, Yoshinobu, Maeda, Tadakazu, Kondo, Masaya, Okada, Kazuhiko, Kakihana, Koji, Kato, Yasushi, Onishi, Kentaro, Fukushima, Shuichi, Taniguchi, Takehiko, Mori, Takayuki, Ishikawa, Yoshihiro, Inamoto, Kuball, J, A Lindemans, C, Jan, Vydra, Achilleas, Anagnostopoulos, Zubeyde, Ozkurt, Zafer, Gulbas, Seckin, Cagirgan, Sinem Civriz Bozdag, Penka, Ganeva, Dobrin, Konstantinov, Kazimierz, Halaburda, Jan, Zaucha, Gergely KrivÃ, N, Isabelina, Ferreira, Joao Forjaz de Lacerda, Alexey, Maschan, and Elena, Parovichnikova

Subjects
Adult, Male, Homologous, medicine.medical_specialty, Ruxolitinib, Adolescent, medicine.medical_treatment, Graft vs Host Disease, Disease, 030204 cardiovascular system & hematology, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Photopheresis, Refractory, Internal medicine, Inolimomab, Nitriles, medicine, Transplantation, Homologous, Humans, Janus Kinase Inhibitors, 030212 general & internal medicine, Child, Glucocorticoids, Aged, Transplantation, Hematology, business.industry, General Medicine, Middle Aged, Thrombocytopenia, humanities, Pyrimidines, surgical procedures, operative, Immunology, Acute Disease, Pyrazoles, Female, business, Glucocorticoid, Stem Cell Transplantation, medicine.drug
Abstract

Acute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; not all patients have a response to standard glucocorticoid treatment. In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory acute GVHD.We conducted a multicenter, randomized, open-label, phase 3 trial comparing the efficacy and safety of oral ruxolitinib (10 mg twice daily) with the investigator's choice of therapy from a list of nine commonly used options (control) in patients 12 years of age or older who had glucocorticoid-refractory acute GVHD after allogeneic stem-cell transplantation. The primary end point was overall response (complete response or partial response) at day 28. The key secondary end point was durable overall response at day 56.A total of 309 patients underwent randomization; 154 patients were assigned to the ruxolitinib group and 155 to the control group. Overall response at day 28 was higher in the ruxolitinib group than in the control group (62% [96 patients] vs. 39% [61]; odds ratio, 2.64; 95% confidence interval [CI], 1.65 to 4.22; P0.001). Durable overall response at day 56 was higher in the ruxolitinib group than in the control group (40% [61 patients] vs. 22% [34]; odds ratio, 2.38; 95% CI, 1.43 to 3.94; P0.001). The estimated cumulative incidence of loss of response at 6 months was 10% in the ruxolitinib group and 39% in the control group. The median failure-free survival was considerably longer with ruxolitinib than with control (5.0 months vs. 1.0 month; hazard ratio for relapse or progression of hematologic disease, non-relapse-related death, or addition of new systemic therapy for acute GVHD, 0.46; 95% CI, 0.35 to 0.60). The median overall survival was 11.1 months in the ruxolitinib group and 6.5 months in the control group (hazard ratio for death, 0.83; 95% CI, 0.60 to 1.15). The most common adverse events up to day 28 were thrombocytopenia (in 50 of 152 patients [33%] in the ruxolitinib group and 27 of 150 [18%] in the control group), anemia (in 46 [30%] and 42 [28%], respectively), and cytomegalovirus infection (in 39 [26%] and 31 [21%]).Ruxolitinib therapy led to significant improvements in efficacy outcomes, with a higher incidence of thrombocytopenia, the most frequent toxic effect, than that observed with control therapy. (Funded by Novartis; REACH2 ClinicalTrials.gov number, NCT02913261.).

Published
2020

36. Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission

Author

Diaz-Beya, M, Labopin, M, Maertens, J, Alijurf, M, Passweg, J, Dietrich, B, Schouten, H, Socie, G, Schaap, N, Schwerdtfeger, R, Volin, L, Michallet, M, Polge, E, Sierra, J, Mohty, M, Esteve, J, Nagler, A, and European Soc Blood Marrow

Subjects
surgical procedures, operative, AML, hemic and lymphatic diseases, 9) AML, DEK-NUP214, prognosis, t(6, allo-SCT
Abstract

Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a poor-risk entity, commonly associated with FLT3-ITD (internal tandem duplication). Allogeneic stem-cell tranplantation (allo-SCT) is recommended, although studies analysing the outcome of allo-SCT in this setting are lacking. We selected 195 patients with t(6;9) AML, who received a first allo-SCT between 2000 and 2016 from the EBMT (European Society for Blood and Marrow Transplantation) registry. Disease status at time of allo-SCT was the strongest independent prognostic factor, with a two-year leukaemia-free survival and relapse incidence of 57% and 19% in patients in CR1 (first complete remission), 34% and 33% in CR2 (second complete remission), and 24% and 49% in patients not in remission, respectively (P < 0 center dot 001). This study, which represents the largest one available in t(6;9) AML, supports the recommendation to submit these patients to allo-SCT in CR1.

Published
2020

41. Chronic graft-versus-host disease features in double unit cord blood transplantation according to National Institutes of Health 2005 cGVHD Consensus criteria

Author

Hayashi, H., Ruggeri, A., Volt, F., Cornelissen, J.J., Socie, G., Sengeloev, H., Michallet, M., Karakasis, D., Petersen, E., Cahn, J.Y., Veelken, H., Mercier, M., Rohrlich, P.S., Rafii, H., Kenzey, C., Xavier, E., Duarte, R.F., Basak, G.W., Rocha, V., Gluckman, E., Eurocord Complications Quality, and Hematology

Subjects
Adult, Lung Diseases, Male, medicine.medical_specialty, Consensus, Adolescent, CONSENSO, Graft vs Host Disease, Consensus criteria, Severity of Illness Index, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Text mining, Internal medicine, medicine, Humans, Cord blood transplantation, Aged, Retrospective Studies, Transplantation, business.industry, Liver Diseases, Hematology, Middle Aged, medicine.disease, United States, Graft-versus-host disease, National Institutes of Health (U.S.), 030220 oncology & carcinogenesis, Chronic Disease, Female, Cord Blood Stem Cell Transplantation, business, 030215 immunology
Published
2018

44. The effect of non-myeloablative conditioning (NMA) versus reduced-intensity conditioning (RIC) in chronic lymphocytic leukaemia (CLL) undergoing allogeneic haematopoietic cell transplantation (allo-HCT): a retrospective EBMT analysis: O153

Author

Andersen, N. S., Vindeløv, L., Karas, M., Gramatzki, M., Machaczka, M., Vitek, A., Stadler, M., Dreger, P., Faber, E., Montserrat, E., Socie, G., Michallet, M., Moreno, C., Niederwieser, D., Bornhäuser, M., Henseler, A., Wreede, L., Gelder, M., Kröger, N., and Schetelig, J.

Published
2013

49. The survival after allogeneic stem cell transplantation for blast crisis chronic myelogenous leukaemia relies on disease status prior to transplant and on the EBMT score, in the tyrosine kinase inhibitors era: P1150

Author

Labussiere, H., Milpied, N., Socie, G., Yakoub-Agha, I., Mohty, M., Fegueux, N., Tilly, H., Blaise, D., Bordigoni, P., Bilger, K., Cordonnier, C., Dalle, J.-H., De Revel, T., Deconinck, E., Rio, B., Sirvent, A., Ifrah, N., Guillerm, G., Mialou, V., Buzyn, A., Huynh, A., Bay, J. O., Raus, N., Morisset, S., Michallet, M., and Nicolini, F.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results